Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Arena Pharmaceuticals Stock Is Surging Higher Today

What happened

Shares of Arena Pharmaceuticals (NASDAQ: ARNA  ) , a small-cap biopharmaceutical company, gained as much as 19.2% in early morning trading today. The catalyst behind this sizable move northward was the company's better-than-expected Q4 earnings report that hit the wires after the market closed yesterday. As of 12:53 p.m. EDT, Arena's shares had cooled off slightly, but were still up by 12.3%.

Woman pointing at an upward trending curve.

Image source: Getty Images.

So what

Arena's recent decision to amend its licensing agreement with Eisai Co. (NASDAQOTH: ESALY  ) for the anti-obesity pill Belviq triggered a much-needed $10 million payment during the fourth quarter, and is expected to lower the company's clinical costs by around $80 million over the next three years. 

These two positive financial offshoots from this newly amended licensing deal with Eisai come at a critical time for Arena. Arena's cash position, after all, was starting to get dangerously low in light of the ongoing costs associated with developing both ralinepag for pulmonary arterial hypertension and etrasimod as a potential treatment for ulcerative colitis. In short, Arena bought itself at least a little more time before it absolutely has to tap the public markets for cash.

Now what

Apart from Arena's modestly improved financial picture, the company also gave an extensive clinical progress report across its entire pipeline. The real headline item on the clinical front, though, is the status of Arena's midstage trials for ralinepag and etrasimod. The company is on track to report top-line data from both trials before the end of the year, which would go a long way toward clarifying Arena's value proposition to investors. 

The downside is that Arena will still need to eventually raise cash sometime soon, perhaps before the middle of the year. And that's not especially great news for shareholders, given that the company's share price is currently hovering around $1.60.

The bottom line is that a large secondary offering -- at least one big enough to cover Arena's clinical expenditures for the next year -- would almost certainly push its share price below the $1 minimum bid requirement for the Nasdaq stock exchange, which suggests that a reverse split may be coming down the pike.

So while Arena appears to be close to turning the corner from a clinical standpoint, it might be wise to simply put this potential comeback story down as a watch list candidate for the moment.

10 stocks we like better than Arena Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Arena Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4008388, ~/Articles/ArticleHandler.aspx, 3/30/2017 4:20:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
Change up DOW 20728.5 69.2 0.3%
Change up S&P 500 2368.1 6.9 0.3%
Change up NASD 5914.3 16.8 0.3%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/30/2017 4:00 PM
ARNA $1.47 Up +0.03 +2.08%
Arena Pharmaceutic… CAPS Rating: ***
ESALY $52.63 Down -0.46 -0.87%
Eisai Co., Ltd (AD… CAPS Rating: No stars

Article registration testing

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 48976878746645666682883218897413